WCTD2016 Abstract Topics Cardiovascular Outcome Studies (12 abstracts)
Efficacy, outcome and safety of SGLT2-I in patients with type II diabetes meta analysis review
Mukunda Singh 1, , Thuy Pham 1, & Marvin Dao 1,
1Clinical Trials, Clinical Trial Network, USA; 2College of Medicine, Windsor University College of Medicine, USA.
Background: SGLT2-I is a promising new class of diabetes pharmacotherapy, it targets blood glucose lowering in both postprandial and fasting states. It offers minimal risk of hypoglycemic events and demonstrates modest effects on blood pressure and weight.
Objective: Meta-analysis review of SGLT2-I outcome, safety and efficacy RCT.
Methods: Medline, EMBASE & CENTRAL were searched until August 2015, double blind RCT in T2DM with at least 12 weeks treatment duration evaluated.
| Study | IND | Duration (Weeks) | Baseline A1c | Change in A1c (%±S.D.) |
| Stenlof et al. | Canagliflozin 300 mg | 26 | 8% | −1.03 |
| Canagliflozin 100 mg | 26 | 8% | −0.77 | |
| Placebo | 26 | 8% | +0.14 | |
| Haring et al. | Empagliflozin 10 mg + Metformin | 24 | 7.90% | −0.7±0.05 |
| Empagliflozin 25 mg + Metformin | 24 | 7.90% | −0.77±0.05 | |
| Ferrannini et al. | Empagliflozin 5 mg + Metformin | 12 | 7.90% | −0.4 |
| Empagliflozin 10 mg + Metformin | 12 | 7.90% | −0.5 | |
| Empagliflozin 25 mg + Metformin | 12 | 7.90% | −0.6 | |
| Placebo + Metformin | 12 | 7.90% | +0.1 | |
| *Note: P<0.001 vs Placebo | ||||
| Potential AE | Genitourinary Infections, Bone Fractures, Diabetic Ketoacidosis, Long term safety not established |
| Cardiovascular Outcomes | Reduction in CV death in patients with known ASCVD; Unclear benefit in primary prevention |
| Hypoglycaemic Event Risk | Low |
| Weight Loss (kg) | 1.5–3.0 |
| SBP Reduction (mmHg) | 3–5 |
Article tools
My recent searches
My recently viewed abstracts
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more